Weimer ET, Ervin SE, Wozniak DJ, et al. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa[J]. Vaccine, 2009, 27(48)：6762-6769.
[4]
Rahner R, Eckhardt A, Duchêne M, et al. Protection of immunosuppressed mice against infection with pseudomonas aeruginosa by monoclonal antibodies to outer membrane protein OprI[J]. Infection, 1990, 18(4)：242-245.
[5]
von Specht BU, Lücking HC, Blum B, et al. The Pseudomonas aeruginosa outer membrane protein I vaccine：immunogenicity and safe administration in man[J]. Behring Inst Mitt, 1997, 98：326-337.
Zhang L, Cai D, Zhao X, et al. Liposomes containing recombinant gp85 protein vaccine against ALV-J in chickens[J]. Vaccine, 2014, 32(21)：2452-2456.
[8]
Tripathi NK, Priya R, Shrivastava A. Production of recombinant Chikungunya virus envelope 2 protein in Escherichia coli[J]. Applied Microbiology and Biotechnology, 2014, 98(6)：2461-2471.
[9]
Xu M, Sun Q, Su J. Microbial transformation of geniposide in Gardenia jasminoides Ellis into genipin by Penicillium nigricans[J]. Enzyme and Microbial Technology, 2008, 42(5)：440-444.
[10]
Corrales-Garcia L, Ortiz E, Casta?eda-Delgado J, et al. Bacterial expression and antibiotic activities of recombinant variants of human β-defensins on pathogenic bacteria and M. tuberculosis[J]. Protein Expression and Purification, 2013, 89(1)：33-43.
[11]
Studier FW. Protein production by auto-induction in high density shaking cultures[J]. Protein Expression and Purification, 2005, 41(1)：207-234.
Loots K, Revets H, Goddeeris BM. Attachment of the outer membrane lipoprotein(OprI)of Pseudomonas aeruginosa to the mucosal surfaces of the respiratory and digestive tract of chickens[J]. Vaccine, 2008, 26(4)：546-551.
[15]
Rau H, Revets H, Cornelis P, et al. Efficacy and functionality of lipoprotein OprI from Pseudomonas aeruginosa as adjuvant for a subunit vaccine against classical swine fever[J]. Vaccine, 2006, 24(22)：4757-4768.
[16]
Westritschnig K, Hochreiter R, Wallner G, et al. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine(IC43)in healthy volunteers[J]. Human Vaccines & Immunotherapeutics, 2014, 10(1)：170-183.
Stryjewska A, Kiepura K, Librowski T, et al. Biotechnology and genetic engineering in the new drug development. Part II monoclonal antibodies, modern vaccines and gene therapy[J]. Pharmacological Reports, 2013, 65(5)：1086-1101.
